United Net Income From Continuing Ops from 2010 to 2024
| UTHR Stock | USD 400.44 9.56 2.33% |
Net Income From Continuing Ops | First Reported 2000-03-31 | Previous Quarter 278.1 M | Current Value 309.1 M | Quarterly Volatility 115.3 M |
Check United Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among United Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 55.9 M, Total Revenue of 2.4 B or Gross Profit of 2.2 B, as well as many indicators such as Price To Sales Ratio of 4.2, Dividend Yield of 0.0114 or PTB Ratio of 1.63. United financial statements analysis is a perfect complement when working with United Therapeutics Valuation or Volatility modules.
United | Net Income From Continuing Ops |
Latest United Therapeutics' Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of United Therapeutics over the last few years. It is United Therapeutics' Net Income From Continuing Ops historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in United Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
United Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | 476,462,667 | |
| Coefficient Of Variation | 66.80 | |
| Mean Deviation | 250,698,711 | |
| Median | 475,800,000 | |
| Standard Deviation | 318,270,423 | |
| Sample Variance | 101296.1T | |
| Range | 1.1B | |
| R-Value | 0.67 | |
| Mean Square Error | 60427.7T | |
| R-Squared | 0.45 | |
| Significance | 0.01 | |
| Slope | 47,531,364 | |
| Total Sum of Squares | 1418144.9T |
United Net Income From Continuing Ops History
About United Therapeutics Financial Statements
United Therapeutics shareholders use historical fundamental indicators, such as Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Although United Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in United Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on United Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Income From Continuing Ops | 984.8 M | 1 B |
Pair Trading with United Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if United Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in United Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against United Stock
| 0.67 | ME | 23Andme Holding | PairCorr |
| 0.62 | DRMA | Dermata Therapeutics | PairCorr |
| 0.59 | VALN | Valneva SE ADR | PairCorr |
| 0.49 | VCNX | Vaccinex | PairCorr |
The ability to find closely correlated positions to United Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace United Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back United Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling United Therapeutics to buy it.
The correlation of United Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as United Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if United Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for United Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for United Stock Analysis
When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.